A startup company that is working to fight cancer is moving to Madison from Chicago on Jan. 1, and is bringing along its first round of funds from investors.

Capio Biosciences has developed technology that can identify cancer cells in the bloodstream, said co-founder and president Seungpyo Hong.

By taking blood samples, or “liquid biopsies,” as a cancer patient goes through treatment, Capio’s device, the OncoSense CTC, can pinpoint cancerous cells and measure them to see how the patient is responding to the treatment, Hong said. Read the full story here.